U.S. Markets closed
  • S&P Futures

    4,210.00
    +0.25 (+0.01%)
     
  • Dow Futures

    33,303.00
    -1.00 (-0.00%)
     
  • Nasdaq Futures

    13,320.50
    +9.25 (+0.07%)
     
  • Russell 2000 Futures

    1,977.00
    +0.70 (+0.04%)
     
  • Crude Oil

    93.96
    -0.38 (-0.40%)
     
  • Gold

    1,785.70
    -4.00 (-0.22%)
     
  • Silver

    20.22
    -0.13 (-0.63%)
     
  • EUR/USD

    1.0315
    -0.0011 (-0.1031%)
     
  • 10-Yr Bond

    2.8880
    +0.1020 (+3.66%)
     
  • Vix

    20.20
    +0.46 (+2.33%)
     
  • GBP/USD

    1.2184
    -0.0018 (-0.1499%)
     
  • USD/JPY

    133.2510
    +0.2520 (+0.1895%)
     
  • BTC-USD

    23,946.34
    -196.09 (-0.81%)
     
  • CMC Crypto 200

    568.28
    -6.47 (-1.12%)
     
  • FTSE 100

    7,465.91
    -41.20 (-0.55%)
     
  • Nikkei 225

    28,376.43
    +557.10 (+2.00%)
     

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Editas Medicine, Inc.
Editas Medicine, Inc.

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a corporate update and results for the fourth quarter and full year 2021.

To access the conference call:

  • U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.

  • Participants should ask to be connected to the Editas Medicine earnings conference call.

A live webcast and replay of the conference call can also be accessed in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Media Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Investor Contact:
Ron Moldaver
(617) 401-9052
ir@editasmed.com